Paoletti E, Taylor J, Meignier B, Meric C, Tartaglia J
Virogenetics Corporation, Troy, NY, USA.
Dev Biol Stand. 1995;84:159-63.
Three highly attenuated and efficacious poxvirus-based vectors, NYVAC, ALVAC and TROVAC, are available for targeted applications as recombinant vaccines in both human and veterinary medicine. The attenuated phenotype of the three vectors is consistent with safe use for vaccination purposes, for the vaccinee, for unvaccinated contacts, and for introduction into the environment. The precise deletion of virulence and host range genes in the NYVAC vector precludes reversion to the virulent phenotype by back mutation. Dissemination of recombinant vaccines based on the NYVAC, ALVAC and TROVAC vectors is highly diminished, because of the genetic engineering in NYVAC and the natural attenuated phenotype of ALVAC and TROVAC. Studies have demonstrated that these recombinant vectors are genetically and phenotypically stable after serial passage in vitro as well as in vivo. NYVAC, ALVAC and TROVAC vectors are the only three poxvirus-based vectors that are classified as BSL1 agents.
三种高度减毒且有效的痘病毒载体，即NYVAC、ALVAC和TROVAC，可作为重组疫苗用于人类和兽医学的靶向应用。这三种载体的减毒表型与用于疫苗接种目的的安全使用相一致，对疫苗接种者、未接种疫苗的接触者以及引入环境中都是安全的。NYVAC载体中毒力和宿主范围基因的精确缺失可防止通过回复突变恢复为有毒表型。由于NYVAC中的基因工程以及ALVAC和TROVAC的天然减毒表型，基于NYVAC、ALVAC和TROVAC载体的重组疫苗的传播性大大降低。研究表明，这些重组载体在体外和体内连续传代后在基因和表型上都是稳定的。NYVAC、ALVAC和TROVAC载体是仅有的三种被归类为BSL1试剂的痘病毒载体。
